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Abstract
Background Glucose management for people with diabetes approaching the end of life can be very challenging. The
aim is to balance a minimally invasive approach with avoidance of symptomatic hypo- and hyperglycaemia.
Case report We present a case of a hospitalized individual whose glucose was managed with closed-loop insulin
delivery within a randomized controlled trial setting during a period of terminal illness. During the time in which closed-
loop insulin delivery was used, glucose control was safe, with no glucose-related harm. The mean  SD sensor glucose for
this individual was 11.3  4.3 mmol/l, percentage of time spent in target glucose range between 6 and 15 mmol/l was
70.5%, time spent in hypoglycaemia was 2.0% and time spent in significant hyperglycaemia >20 mmol/l was 2.6%.
Conclusion Closed-loop systems can accommodate personalized glucose targets and highly variable insulin require-
ments. Factory-calibrated continuous glucose sensors and insulin pump therapy are less intrusive than finger-stick
glucose measurements and insulin injections, respectively. Closed-loop systems may provide a safer and less burdensome
approach to glucose management towards the end of life.
Diabet. Med. 36, 1711–1714 (2019)
Introduction
Diabetes is one of the commonest comorbidities in end-of-life
care and management of blood glucose during this period can
be challenging [1,2]. Pathophysiological changes occur
towards the end of life, predisposing to accentuated pertur-
bations of glucose levels; hyperglycaemia may result from the
stress response to severe illness, use of steroids for symptom
relief or co-existent infections [3]. Insulin requirements may
fall as a result of reduced oral intake and weight loss, and
renal or hepatic failure, with the consequent risk of hypo-
glycaemia [4,5].
End-of-life diabetes care requires a holistic approach;
blood glucose monitoring should be minimized and com-
plex insulin regimens avoided. It is important, however, to
maintain adequate control to enhance comfort by
preventing hyperglycaemia-induced thirst, dehydration,
confusion, drowsiness and symptomatic hypoglycaemia
[2]. Clinical recommendations are not evidence-based but
recommend target glucose levels between 6 and 15 mmol/l,
with as minimally invasive an insulin regimen and as
infrequent monitoring as possible to keep the person
comfortable without compromising safety [4,6]. Despite
these recommendations, clinical practice is highly variable
[2,4].
The role of diabetes technologies in improving the quality
and experience of diabetes care for patients and relatives
towards the end of life has not been determined. Closed-loop
systems, which combine real-time glucose measurements
from a continuous glucose monitor with a control algorithm
that directs insulin delivery via an insulin pump have been
shown to be safe and effective in the inpatient setting [7,8].
Closed-loop systems, which automatically deliver insulin in a
glucose-responsive manner, may provide a solution to
glucose management for people hospitalized towards the
end of life.
Correspondence to: Roman Hovorka. E-mail: rh347@cam.ac.uk
This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
ª 2019 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK 1711
DIABETICMedicine
DOI: 10.1111/dme.13974
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
83
61
 
| 
do
wn
lo
ad
ed
: 
27
.1
.2
02
0
In this case report we describe the case of a participant in a
randomized controlled trial whose glucose was managed
safely with a closed-loop system during a period of terminal
illness.
Case report
The individual in this case was a 79-year-old woman who
presented with vomiting, increased stoma output and vertigo.
She had a medical history of surgically resected bowel cancer,
hypothyroidism, deep vein thrombosis treated with tinza-
parin, and Type 2 diabetes mellitus managed with oral
hypoglycaemic agents (metformin and linagliptin). Prior to
admission she was independent in activities of daily living. A
computerized tomography (CT) scan at presentation showed
a large posterior fossa haemorrhage, which was managed
with reversal of tinzaparin and blood pressure control.
Metformin was stopped on admission as a result of
dehydration from increased stoma output, and the woman
received corrective doses of aspart as required to treat
hyperglycaemia.
Subsequently, the woman developed increased confusion
and drowsiness, and repeat CT scan showed mass effect with
hydrocephalus. She was transferred to the regional neuro-
surgical unit and an external ventricular drain inserted.
Hyperglycaemia was initially managed with a variable rate
intravenous insulin infusion with 2–4 units/h, but hypergly-
caemia persisted (capillary blood glucose levels 12–16 mmol/
l). Nasogastric feeding was commenced because of fluctuat-
ing consciousness [Glasgow Coma Scale 8–14] with Nutrison
protein Plus 50 ml/h for 20 h (7.1 g carbohydrate/h), with a
4-h break, and this was subsequently uptitrated to 75 ml/h
(10.7 g carbohydrate/h).
Randomized controlled trial setting
During the woman’s stay in the hospital, we were undertak-
ing a multinational randomized controlled trial contrasting
fully closed-loop insulin delivery with faster-acting insulin
aspart (Fiasp; Novo Nordisk, Bagsværd, Denmark), or
conventional subcutaneous insulin therapy over a period of
up to 15 days of hospital stay [9]. In the UK, the study
protocol was approved by the local Research Ethics Com-
mittees (East of England Central Cambridge Ethics Com-
mittee) and the Medicines and Healthcare products
Regulatory Agency (MHRA).
Recruitment of this particular woman into the study was
discussed with her family, and a consultee declaration form
was signed by her next-of-kin. Although prognosis was
guarded, there were no limits to treatment escalation at the
time of recruitment into the study. The woman was
randomized to closed-loop insulin delivery. Pre-study total
daily insulin dose was 110 units.
Closed-loop insulin delivery
A subcutaneous cannula was inserted into the abdomen/arm
for delivery of faster-acting insulin aspart by insulin pump
(Dana R Diabecare; SOOIL Development, Seoul, Korea). A
subcutaneous real-time continuous glucose monitor (Free-
style Navigator II; Abbott Diabetes Care, Alameda, CA,
USA) was inserted into the abdomen/arm and calibrated
according to manufacturer’s instructions (Fig. 1).
The FlorenceD2W-T2 closed-loop system consisted of a
model predictive control algorithm (version 0.3.70) residing
on a control algorithm device (Dell Latitude 10 Tablet, Dell,
FIGURE 1 Automated fully closed-loop insulin delivery prototype (FlorenceD2W-T2) used by the woman in our case report (photo obtained with
consent)
What’s new?
• Glucose management for people with diabetes
approaching the end of life can be very challenging,
and clinical practice is variable.
• We present a case where closed-loop insulin delivery
was used to manage glucose levels in an individual
hospitalized during a period of terminal illness.
• During the time in which closed-loop insulin delivery
was used, glucose control was safe, with no glucose-
related harm.
• Closed-loop systems may provide a safer and less
burdensome approach to glucose management towards
the end of life.
• Studies are needed to determine safety, efficacy and
acceptability in this population.
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UK) linked by a USB cable to the continuous glucose
monitoring receiver (FreeStyle Navigator II). The tablet
device communicated with the study pump via a Bluetooth
wireless communication protocol. The control algorithm was
initialized using the woman’s weight and pre-study total
daily insulin dose. The control algorithm did not receive
announcements regarding timing or carbohydrate content of
meals, enteral or parenteral feeds. No adjustments to target
glucose were made during the study.
The control algorithm adapted itself to a particular
participant by updating model variables and refining partic-
ipant’s insulin requirements. The algorithm aimed to achieve
glucose levels between 5.8 and 7.2 mmol/l, and adjusted the
actual target level depending on accuracy of the model-based
glucose predictions and prevailing glucose levels. Safety rules
limited maximum insulin infusion and suspended insulin
delivery at sensor glucose ≤4.2 mmol/l, or when sensor
glucose was rapidly decreasing. If sensor glucose was
unavailable for 30 min, the research team was alerted and
the study pump insulin infusion rate reverted to the pre-
programmed basal rate.
Results
During the study period, after 2 days of closed-loop insulin
delivery, the woman developed hospital acquired pneumo-
nia. Antibiotics, oxygen therapy and chest physiotherapy
were commenced and closed-loop was continued, with
notably higher insulin requirements (Fig. 2). Despite optimal
ward-based treatment, her clinical condition deteriorated
and clinical focus switched to palliation; the nasogastric feed
was stopped and, as insulin requirements were minimal
without the feed, closed-loop and participation in the study
were stopped at this point. A syringe driver was started for
symptom control and she died several days later. The death
was reported to the trial Data and Safety Monitoring Board
as an adverse event unrelated to study devices and proce-
dures.
During the period of closed-loop insulin delivery, glucose
control was safe with no glucose-related harm. The mean
sensor glucose was 11.3  4.3 mmol/l and percentage of time
with sensor glucose between 6 and 15 mmol/l was 70.5%.
Time spent in hypoglycaemia <3.9 mmol/l was 2.0% and
time spent in significant hyperglycaemia >20 mmol/l was
2.6%.
Discussion
This case suggests that closed-loop insulin delivery can
achieve safe glucose control in a hospitalized person with
complex comorbidities during their terminal illness.
Closed-loop systems deliver insulin in a glucose-responsive
manner, accommodating highly variable day-to-day insulin
requirements, which are commonly seen during clinical
deterioration and as people approach the end of life. Safe
glucose control, avoiding hypoglycaemia and symptomatic
D1 
D2 
D3 
FIGURE 2 Sensor glucose levels (red line), closed-loop algorithm directed insulin delivery (blue line) during the period of closed-loop glucose control
(D1, 2 and 3 are consecutive days of closed-loop insulin delivery during the study). Black filled line above graph indicates ongoing nasogastric
feeding and unfilled indicates feed discontinued. Arrow indicates clinical deterioration with hospital-acquired pneumonia.
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hyperglycaemia can be difficult to achieve with standard
subcutaneous insulin therapy in this clinical setting. Person-
alized glucose targets can be applied to the closed-loop
algorithm, allowing higher glucose levels while still main-
taining adequate glucose control to prevent symptomatic
hypo- or hyperglycaemia.
Closed-loop technology may be a feasible option to reduce
the burden of glucose management for people with diabetes
who require insulin towards the end of life. Factory-
calibrated continuous glucose monitors require no calibra-
tions, making this approach less invasive than standard
finger-stick capillary blood glucose monitoring; however
accuracy of non-calibrated continuous glucose monitors in
the inpatient setting, and in those approaching the end of life,
has not been evaluated. Insulin delivery via subcutaneous
insulin pump is also less intrusive than multiple daily insulin
injections.
Closed-loop insulin delivery offers a novel approach to
glucose management for people with diabetes who require
insulin towards the end of life, and may be safer and less
burdensome than standard insulin therapy. Acceptability of
this technology to people with diabetes, family members and
healthcare professionals at this time needs to be determined,
and trials of safety and efficacy in this population undertaken.
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